
样式: 排序: IF: - GO 导出 标记为已读
-
Oral eltanexor treatment of patients with higher-risk myelodysplastic syndrome refractory to hypomethylating agents J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-08-03 Lee, Sangmin, Mohan, Sanjay, Knupp, Jessica, Chamoun, Kamal, de Jonge, Adrienne, Yang, Fan, Baloglu, Erkan, Shah, Jatin, Kauffman, Michael G., Shacham, Sharon, Bhatnagar, Bhavana
Patients with higher-risk myelodysplastic syndromes (MDS) refractory to hypomethylating agents (HMAs) have limited therapeutic options and an expected overall survival (OS) of 3–5 months. Eltanexor is an investigational oral selective inhibitor of nuclear export with low central nervous system penetrance and an acceptable tolerability profile. Preclinical studies suggest that myeloid malignancies are
-
Correction: hUC-EVs-ATO reduce the severity of acute GVHD by resetting inflammatory macrophages toward the M2 phenotype J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-07-31 Su, Yan, Sun, Xueyan, Liu, Xiao, Qu, Qingyuan, Yang, Liping, Chen, Qi, Liu, Fengqi, Li, Yueying, Wang, Qianfei, Huang, Bo, Zhang, Xiao-Hui, Huang, Xiao-Jun
The original article [1] contained errors in the names of co-authors, Xiao-Jun Huang and Xiao-Hui Zhang which have since been corrected. Su Y, Sun X, Liu X, et al. hUC-EVs-ATO reduce the severity of acute GVHD by resetting inflammatory macrophages toward the M2 phenotype. J Hematol Oncol. 2022;15:99. https://doi.org/10.1186/s13045-022-01315-2. Article PubMed PubMed Central Google Scholar Download referencesAuthor
-
NBAS, a gene involved in cytotoxic degranulation, is recurrently mutated in pediatric hemophagocytic lymphohistiocytosis J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-07-28 Bi, Xiaoman, Zhang, Qing, Chen, Lei, Liu, Dan, Li, Yueying, Zhao, Xiaoxi, Zhang, Ya, Zhang, Liping, Liu, Jingkun, Wu, Chaoyi, Li, Zhigang, Zhao, Yunze, Ma, Honghao, Huang, Gang, Liu, Xin, Wang, Qian-fei, Zhang, Rui
Hemophagocytic lymphohistiocytosis (HLH), particularly primary HLH (pHLH), is a rare, life-threatening disease. Germline genetic deficiency of 12 known HLH genes impairs cytotoxic degranulation in natural killer (NK) cells or cytotoxic T lymphocytes (CTLs) and contributes to pHLH development. However, no pathogenic mutations in these HLH genes are found in nearly 10% of HLH patients, despite a strong
-
Correction: Innate immune mediator, Interleukin-1 receptor accessory protein (IL1RAP), is expressed and pro-tumorigenic in pancreatic cancer J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-07-26 Zhang, Yang, Chen, Xiaoyi, Wang, Huamin, Gordon-Mitchell, Shanisha, Sahu, Srabani, Bhagat, Tushar D., Choudhary, Gaurav, Aluri, Srinivas, Pradhan, Kith, Sahu, Plabani, Carbajal, Milagros, Zhang, Hui, Agarwal, Beamon, Shastri, Aditi, Martell, Robert, Starczynowski, Daniel, Steidl, Ulrich, Maitra, Anirban, Verma, Amit
The original article erroneously omitted the following Conflict of Interest statement: Dr. Maitra receives royalties from Cosmos Wisdom Biotech for a license related to a pancreatic cancer early detection test. He is also listed as an inventor on a patent licensed to Thrive Earlier Detection Ltd (an Exact Sciences Company) and serves as a consultant for Freenome and Tezcat Biotechnology. Authors and
-
hUC-EVs-ATO reduce the severity of acute GVHD by resetting inflammatory macrophages toward the M2 phenotype J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-07-21 Su, Yan, Sun, Xueyan, Liu, Xiao, Qu, Qingyuan, Yang, Liping, Chen, Qi, Liu, Fengqi, Li, Yueying, Wang, Qianfei, Huang, Bo, Huang, Xiao-Hui, Zhang, Xiao-Jun
Both extracellular vesicles from mesenchymal stromal cell-derived human umbilical cords (hUC-EVs) and arsenic trioxides (ATOs) have been demonstrated to treat acute graft-versus-host disease (aGVHD) via immunomodulation. Apart from immunomodulation, hUC-EVs have a unique function of drug delivery, which has been proposed to enhance their efficacy. In this study, we first prepared ATO-loaded hUC-EVs
-
The mitochondrial unfolded protein response (UPRmt): shielding against toxicity to mitochondria in cancer J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-07-21 Inigo, Joseph R., Chandra, Dhyan
Mitochondria are essential for tumor growth and progression. However, the heavy demand for mitochondrial activity in cancer leads to increased production of mitochondrial reactive oxygen species (mtROS), accumulation of mutations in mitochondrial DNA, and development of mitochondrial dysfunction. If left unchecked, excessive mtROS can damage and unfold proteins in the mitochondria to an extent that
-
Mitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-07-18 Jin, Ping, Jiang, Jingwen, Zhou, Li, Huang, Zhao, Nice, Edouard C., Huang, Canhua, Fu, Li
Drug resistance represents a major obstacle in cancer management, and the mechanisms underlying stress adaptation of cancer cells in response to therapy-induced hostile environment are largely unknown. As the central organelle for cellular energy supply, mitochondria can rapidly undergo dynamic changes and integrate cellular signaling pathways to provide bioenergetic and biosynthetic flexibility for
-
Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort study J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-07-16 Epperla, Narendranath, Zhao, Qiuhong, Chowdhury, Sayan Mullick, Shea, Lauren, Moyo, Tamara K., Reddy, Nishitha, Sheets, Julia, Weiner, David M., Geethakumari, Praveen Ramakrishnan, Kandarpa, Malathi, Bruno, Ximena Jordan, Thomas, Colin, Churnetski, Michael C., Hsu, Andrew, Zurbriggen, Luke, Tan, Cherie, Lindsey, Kathryn, Maakaron, Joseph, Caimi, Paolo F., Torka, Pallawi, Bello, Celeste, Ayyappan, Sabarish
Ibrutinib is effective in the treatment of relapsed/refractory (R/R) marginal zone lymphoma (MZL) with an overall response rate (ORR) of 48%. However, factors associated with response (or lack thereof) to ibrutinib in R/R MZL in clinical practice are largely unknown. To answer this question, we performed a multicenter (25 US centers) cohort study and divided the study population into three groups:
-
Exploring immunotherapy in colorectal cancer J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-07-16 Weng, Junyong, Li, Shanbao, Zhu, Zhonglin, Liu, Qi, Zhang, Ruoxin, Yang, Yufei, Li, Xinxiang
Chemotherapy combined with or without targeted therapy is the fundamental treatment for metastatic colorectal cancer (mCRC). Due to the adverse effects of chemotherapeutic drugs and the biological characteristics of the tumor cells, it is difficult to make breakthroughs in traditional strategies. The immune checkpoint blockades (ICB) therapy has made significant progress in the treatment of advanced
-
Emerging strategies to overcome resistance to third-generation EGFR inhibitors J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-07-15 Shi, Kunyu, Wang, Guan, Pei, Junping, Zhang, Jifa, Wang, Jiaxing, Ouyang, Liang, Wang, Yuxi, Li, Weimin
Epidermal growth factor receptor (EGFR), the receptor for members of the epidermal growth factor family, regulates cell proliferation and signal transduction; moreover, EGFR is related to the inhibition of tumor cell proliferation, angiogenesis, invasion, metastasis, and apoptosis. Therefore, EGFR has become an important target for the treatment of cancer, including non-small cell lung cancer, head
-
Allosteric activation of the metabolic enzyme GPD1 inhibits bladder cancer growth via the lysoPC-PAFR-TRPV2 axis J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-07-14 Zhang, Wenlong, He, Xin, Yin, Haoli, Cao, Wenmin, Lin, Tingsheng, Chen, Wei, Diao, Wenli, Ding, Meng, Hu, Hao, Mo, Wenjing, Zhang, Qing, Guo, Hongqian
Bladder cancer is the most common malignant tumor of the urinary system. Surgical resection and chemotherapy are the two mainstream treatments for bladder cancer. However, the outcomes are not satisfactory for patients with advanced bladder cancer. There is a need to further explore more effective targeted therapeutic strategies. Proteomics were performed to compare protein expression differences between
-
Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-07-14 Chen, Sunnia T., Azali, Leylah, Rosen, Lindsay, Zhao, Qiuhong, Wiczer, Tracy, Palettas, Marilly, Gambril, John, Kola-Kehinde, Onaopepo, Ruz, Patrick, Kalathoor, Sujay, Rogers, Kerry, Kittai, Adam, Grever, Michael, Awan, Farrukh, Byrd, John C., Woyach, Jennifer, Bhat, Seema A., Addison, Daniel
Post-market analyses revealed unanticipated links between first-generation Bruton’s tyrosine kinase inhibitor (BTKi) therapy, ibrutinib, and profound early hypertension. Yet, whether this is seen with novel selective second (next)-generation BTKi therapy, acalabrutinib, is unknown. Leveraging a large cohort of consecutive B cell cancer patients treated with acalabrutinib from 2014 to 2020, we assessed
-
Targeting p53–MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-07-13 Zhu, Haohao, Gao, Hui, Ji, Yingying, Zhou, Qin, Du, Zhiqiang, Tian, Lin, Jiang, Ying, Yao, Kun, Zhou, Zhenhe
p53, encoded by the tumor suppressor gene TP53, is one of the most important tumor suppressor factors in vivo and can be negatively regulated by MDM2 through p53–MDM2 negative feedback loop. Abnormal p53 can be observed in almost all tumors, mainly including p53 mutation and functional inactivation. Blocking MDM2 to restore p53 function is a hotspot in the development of anticancer candidates. Till
-
A clinician perspective on the treatment of chronic myeloid leukemia in the chronic phase J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-07-11 García-Gutiérrez, Valentin, Breccia, Massimo, Jabbour, Elias, Mauro, Michael, Cortes, Jorge E.
Tyrosine kinase inhibitors (TKIs) have vastly improved long-term outcomes for patients with chronic myeloid leukemia (CML). After imatinib (a first-generation TKI), second- and third-generation TKIs were developed. With five TKIs (imatinib, dasatinib, bosutinib, nilotinib, and ponatinib) targeting BCR::ABL approved in most countries, and with the recent approval of asciminib in the USA, treatment decisions
-
Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-07-07 Liu, Yun, Li, Yang, Wang, Yuxi, Lin, Congcong, Zhang, Dan, Chen, Juncheng, Ouyang, Liang, Wu, Fengbo, Zhang, Jifa, Chen, Lei
Vascular endothelial growth factor receptors (VEGFRs) are a family of receptor protein tyrosine kinases that play an important role in the regulation of tumor-induced angiogenesis. Currently, VEGFR inhibitors have been widely used in the treatment of various tumors. However, current VEGFR inhibitors are limited to a certain extent due to limited clinical efficacy and potential toxicity, which hinder
-
First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-07-07 Jin, Xin, Zhang, Meng, Sun, Rui, Lyu, Hairong, Xiao, Xia, Zhang, Xiaomei, Li, Fan, Xie, Danni, Xiong, Xia, Wang, Jiaxi, Lu, Wenyi, Zhang, Hongkai, Zhao, Mingfeng
Relapsed or refractory (R/R) acute myeloid leukemia (AML) has a poor prognosis. In this study, we evaluated chimeric antigen receptor (CAR) T cell therapy targeting CLL-1 in adults with R/R AML patients. Patients received conditioning chemotherapy with cyclophosphamide (500 mg/m2) and fludarabine (30 mg/m2) for 3 days and an infusion of a dose of 1–2 × 106 CAR-T cells/kg. The incidence of dose-limiting
-
Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-07-07 Xu, Liangliang, Zou, Chang, Zhang, Shanshan, Chu, Timothy Shun Man, Zhang, Yan, Chen, Weiwei, Zhao, Caining, Yang, Li, Xu, Zhiyuan, Dong, Shaowei, Yu, Hao, Li, Bo, Guan, Xinyuan, Hou, Yuzhu, Kong, Feng-Ming
The development of combination immunotherapy based on the mediation of regulatory mechanisms of the tumor immune microenvironment (TIME) is promising. However, a deep understanding of tumor immunology must involve the systemic tumor immune environment (STIE) which was merely illustrated previously. Here, we aim to review recent advances in single-cell transcriptomics and spatial transcriptomics for
-
Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2) J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-07-06 Zhao, Wan-Hong, Wang, Bai-Yan, Chen, Li-Juan, Fu, Wei-Jun, Xu, Jie, Liu, Jie, Jin, Shi-Wei, Chen, Yin-Xia, Cao, Xing-Mei, Yang, Yun, Zhang, Yi-Lin, Wang, Fang-Xia, Zhang, Peng-Yu, Lei, Bo, Gu, Liu-Fang, Wang, Jian-Li, Zhang, Hui, Bai, Ju, Xu, Yan, Zhu, Han, Du, Juan, Jiang, Hua, Fan, Xiao-Hu, Li, Jian-Yong, Hou, Jian, Chen, Zhu, Zhang, Wang-Gang, Mi, Jian-Qing, Chen, Sai-Juan, He, Ai-Li
LCAR-B38M is a chimeric antigen receptor T cell product with two binding domains targeting B cell maturation antigen. Our previous reports showed a remarkable efficacy of LCAR-B38M in patients with relapsed/refractory multiple myeloma (RRMM) at a median follow-up of 2 years. Here, we report long-term safety and efficacy data from a median follow-up of 4 years. LEGEND-2 was a phase 1, single-arm, open-label
-
Long noncoding RNA Smyca coactivates TGF-β/Smad and Myc pathways to drive tumor progression J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-07-06 Chen, Hsin-Yi, Chan, Shu-Jou, Liu, Xinxin, Wei, An-Chi, Jian, Ru-In, Huang, Kuan-Wei, Lang, Yaw-Dong, Shih, Jou-Ho, Liao, Chun-Chieh, Luan, Chiu-Lin, Kao, Yu-Tung, Chiang, Shang-Yin, Hsiao, Pei-Wen, Jou, Yuh-Shan, Chen, Yunching, Chen, Ruey-Hwa
Metastasis and chemoresistance are major culprits of cancer mortality, but factors contributing to these processes are incompletely understood. Bioinformatics methods were used to identify the relations of Smyca expression to clinicopathological features of human cancers. RNA-sequencing analysis was used to reveal Smyca-regulated transcriptome. RNA pull-down and RNA immunoprecipitation were used to
-
Crosstalk among m6A RNA methylation, hypoxia and metabolic reprogramming in TME: from immunosuppressive microenvironment to clinical application J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-07-06 Zhang, Fusheng, Liu, Haiyang, Duan, Meiqi, Wang, Guang, Zhang, Zhenghou, Wang, Yutian, Qian, Yiping, Yang, Zhi, Jiang, Xiaofeng
The tumor microenvironment (TME), which is regulated by intrinsic oncogenic mechanisms and epigenetic modifications, has become a research hotspot in recent years. Characteristic features of TME include hypoxia, metabolic dysregulation, and immunosuppression. One of the most common RNA modifications, N6-methyladenosine (m6A) methylation, is widely involved in the regulation of physiological and pathological
-
Emerging role of exosomes in cancer progression and tumor microenvironment remodeling J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-06-28 Paskeh, Mahshid Deldar Abad, Entezari, Maliheh, Mirzaei, Sepideh, Zabolian, Amirhossein, Saleki, Hossein, Naghdi, Mohamad Javad, Sabet, Sina, Khoshbakht, Mohammad Amin, Hashemi, Mehrdad, Hushmandi, Kiavash, Sethi, Gautam, Zarrabi, Ali, Kumar, Alan Prem, Tan, Shing Cheng, Papadakis, Marios, Alexiou, Athanasios, Islam, Md Asiful, Mostafavi, Ebrahim, Ashrafizadeh, Milad
Cancer is one of the leading causes of death worldwide, and the factors responsible for its progression need to be elucidated. Exosomes are structures with an average size of 100 nm that can transport proteins, lipids, and nucleic acids. This review focuses on the role of exosomes in cancer progression and therapy. We discuss how exosomes are able to modulate components of the tumor microenvironment
-
The regulation of insulin receptor/insulin-like growth factor 1 receptor ratio, an important factor for breast cancer prognosis, by TRIP-Br1 J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-06-16 Nguyen, Thi Ngoc Quynh, Jung, Samil, Nguyen, Hai Anh, Lee, BeomSuk, Vu, Son Hai, Myagmarjav, Davaajargal, Eum, Hye Hyeon, Lee, Hae-Ock, Jo, Taeyeon, Choi, Yeongseon, Lee, Myeong-Sok
Much higher risk of cancer has been found in diabetes patients. Insulin receptor (IR) and insulin-like growth factor 1 receptor (IGF1R) have been extensively studied in both breast cancer and diabetes therapies. Interestingly, a recent study proposed that IR/IGF1R ratio is an important factor for breast cancer prognosis. Women with higher IR/IGF1R ratio showed poor breast cancer prognosis as well as
-
Immune response to vaccination against SARS-CoV-2 in hematopoietic stem cell transplantation and CAR T-cell therapy recipients J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-06-16 Wu, Xi, Wang, Lu, Shen, Lu, He, Lin, Tang, Kefu
Recipients after hematopoietic stem cell transplantation (HSCT) or chimeric antigen receptor T-cell (CAR-T) therapy are at increased risk for unfavorable outcomes after SARS-CoV-2 infection. The efficacy of COVID-19 vaccines remains undetermined in this vulnerable population, we therefore conducted a pooled analysis to evaluate the immune response after vaccination. A total of 46 studies were finally
-
Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-06-11 Kreatsoulas, Daniel, Bolyard, Chelsea, Wu, Bill X., Cam, Hakan, Giglio, Pierre, Li, Zihai
Despite recent advances in cancer therapeutics, glioblastoma (GBM) remains one of the most difficult cancers to treat in both the primary and recurrent settings. GBM presents a unique therapeutic challenge given the immune-privileged environment of the brain and the aggressive nature of the disease. Furthermore, it can change phenotypes throughout the course of disease—switching between mesenchymal
-
Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-06-11 Fujino, Toshio, Suda, Kenichi, Koga, Takamasa, Hamada, Akira, Ohara, Shuta, Chiba, Masato, Shimoji, Masaki, Takemoto, Toshiki, Soh, Junichi, Mitsudomi, Tetsuya
Capmatinib and tepotinib are guideline-recommended front-line treatments for non-small-cell lung cancer (NSCLC) patients with MET exon 14 skipping mutations (METex14). However, the emergence of acquired resistance to capmatinib/tepotinib is almost inevitable partially due to D1228X or Y1230X secondary mutations of the MET. In this study, we explored agents that are active against both D1228X and Y1230X
-
Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient? J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-06-07 Kegyes, David, Constantinescu, Catalin, Vrancken, Louise, Rasche, Leo, Gregoire, Celine, Tigu, Bogdan, Gulei, Diana, Dima, Delia, Tanase, Alina, Einsele, Hermann, Ciurea, Stefan, Tomuleasa, Ciprian, Caers, Jo
Multiple myeloma (MM) is a plasma cell malignancy that affects an increasing number of patients worldwide. Despite all the efforts to understand its pathogenesis and develop new treatment modalities, MM remains an incurable disease. Novel immunotherapies, such as CAR T cell therapy (CAR) and bispecific T cell engagers (BiTE), are intensively targeting different surface antigens, such as BMCA, SLAMF7
-
Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-06-03 Wu, Qinghua, You, Li, Nepovimova, Eugenie, Heger, Zbynek, Wu, Wenda, Kuca, Kamil, Adam, Vojtech
Hypoxia, a common feature of the tumor microenvironment in various types of cancers, weakens cytotoxic T cell function and causes recruitment of regulatory T cells, thereby reducing tumoral immunogenicity. Studies have demonstrated that hypoxia and hypoxia-inducible factors (HIFs) 1 and 2 alpha (HIF1A and HIF2A) are involved in tumor immune escape. Under hypoxia, activation of HIF1A induces a series
-
Integrated proteogenomic characterization of urothelial carcinoma of the bladder J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-06-03 Xu, Ning, Yao, Zhenmei, Shang, Guoguo, Ye, Dingwei, Wang, Haixing, Zhang, Hailiang, Qu, Yuanyuan, Xu, Fujiang, Wang, Yunzhi, Qin, Zhaoyu, Zhu, Jiajun, Zhang, Fan, Feng, Jinwen, Tian, Sha, Liu, Yang, Zhao, Jianyuan, Hou, Jun, Guo, Jianming, Hou, Yingyong, Ding, Chen
Urothelial carcinoma (UC) is the most common pathological type of bladder cancer, a malignant tumor. However, an integrated multi-omics analysis of the Chinese UC patient cohort is lacking. We performed an integrated multi-omics analysis, including whole-exome sequencing, RNA-seq, proteomic, and phosphoproteomic analysis of 116 Chinese UC patients, comprising 45 non-muscle-invasive bladder cancer patients
-
Clinical experiences with venetoclax and other pro-apoptotic agents in lymphoid malignancies: lessons from monotherapy and chemotherapy combination J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-06-03 Lew, Thomas E., Seymour, John F.
BH3-mimetics are a novel drug class of small molecule inhibitors of BCL2 family proteins which restore apoptosis in malignant cells. The only currently approved BH3-mimetic, the selective BCL2 inhibitor venetoclax, is highly efficacious in chronic lymphocytic leukemia and has rapidly advanced to an approved standard of care in frontline and relapsed disease in combination with anti-CD20 monoclonal
-
How we treat NK/T-cell lymphomas J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-06-03 Tse, Eric, Zhao, Wei-Li, Xiong, Jie, Kwong, Yok-Lam
Natural killer (NK)/T-cell lymphomas are aggressive malignancies with a predilection for Asian and South American populations. Epstein–Barr virus (EBV) infection in lymphoma cells is universal. Predominantly extranodal, NK/T-cell lymphomas are divided clinically into nasal (involving the nose and upper aerodigestive tract), non-nasal (involving the skin, gastrointestinal tract, testes, and other organs)
-
DTX-P7, a peptide–drug conjugate, is highly effective for non-small cell lung cancer J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-06-03 Jiang, Yao, Huang, Wei, Sun, Xiaojiao, Yang, Xiaozhou, Wu, Youming, Shi, Jiaojiao, Zheng, Ji, Fan, Shujie, Liu, Junya, Wang, Jun, Liang, Zhen, Yang, Nan, Liu, Zhenming, Liu, Yanyong
Despite tremendous success of molecular targeted therapy together with immunotherapy, only a small subset of patients can benefit from them. Chemotherapy remains the mainstay treatment for most of tumors including non-small cell lung cancer (NSCLC); however, non-selective adverse effects on healthy tissues and secondary resistance are the main obstacles. Meanwhile, the quiescent or dormant cancer stem-like
-
Mammary adipocytes protect triple-negative breast cancer cells from ferroptosis J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-06-03 Xie, Yizhao, Wang, Biyun, Zhao, Yannan, Tao, Zhonghua, Wang, Ye, Chen, Guangliang, Hu, Xichun
Ferroptosis, a novel non-apoptotic form of cell death, can induce tumor cell death and treatment resistance. Lipid metabolism is closely related to ferroptosis; however, the effect of mammary adipocytes on breast cancer ferroptosis remains to be elucidated. Here, we established the co-culture system of adipocyte-breast cancer cells and revealed the protection of triple-negative breast cancer from ferroptosis
-
Correction to: COVID-19 in pediatric cancer patients is associated with treatment interruptions but not with short-term mortality: a Polish national study J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-05-31 Węcławek-Tompol, Jadwiga, Zakrzewska, Zuzanna, Gryniewicz-Kwiatkowska, Olga, Pierlejewski, Filip, Bień, Ewa, Zaucha-Prażmo, Agnieszka, Zając-Spychała, Olga, Szmydki-Baran, Anna, Mizia-Malarz, Agnieszka, Bal, Wioletta, Sawicka-Żukowska, Małgorzata, Kruk, Agnieszka, Ociepa, Tomasz, Raciborska, Anna, Książek, Agnieszka, Szczepański, Tomasz, Peregud-Pogorzelski, Jarosław, Krawczuk-Rybak, Maryna, Chaber
The original article [1] mistakenly omitted two co-authors—Tomasz Ociepa and Ninela Irga-Jaworska—who have both since been re-instated into the authorship. Węcławek-Tompol, et al. COVID-19 in pediatric cancer patients is associated with treatment interruptions but not with short-term mortality: a Polish national study. J Hematol Oncol. 2021;14:1–10. https://doi.org/10.1186/s13045-021-01181-4. CAS Article
-
Innate immune mediator, Interleukin-1 receptor accessory protein (IL1RAP), is expressed and pro-tumorigenic in pancreatic cancer J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-05-23 Zhang, Yang, Chen, Xiaoyi, Wang, Huamin, Gordon-Mitchell, Shanisha, Sahu, Srabani, Bhagat, Tushar D., Choudhary, Gaurav, Aluri, Srinivas, Pradhan, Kith, Sahu, Plabani, Carbajal, Milagros, Zhang, Hui, Agarwal, Beamon, Shastri, Aditi, Martell, Robert, Starczynowski, Daniel, Steidl, Ulrich, Maitra, Anirban, Verma, Amit
Advanced pancreatic ductal adenocarcinoma (PDAC) is usually an incurable malignancy that needs newer therapeutic targets. Interleukin-1 receptor accessory protein (IL1RAP) is an innate immune mediator that regulates activation of pro-inflammatory and mitogenic signaling pathways. Immunohistochemistry on tissue microarrays demonstrated expression of IL1RAP in majority of human PDAC specimens and in
-
Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism: 2022 updated systematic review and meta-analysis of randomized controlled trials J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-05-21 Frere, Corinne, Farge, Dominique, Schrag, Deborah, Prata, Pedro H., Connors, Jean M.
International clinical practice guidelines have progressively endorsed direct oral anticoagulants (DOACs) as an alternative to low-molecular-weight heparins (LMWHs) monotherapy for the initial and long-term treatment of cancer-associated thrombosis (CAT). Several new randomized controlled trials (RCTs) have recently reported additional results on the safety and efficacy of DOACs in this setting. We
-
C3aR costimulation enhances the antitumor efficacy of CAR-T cell therapy through Th17 expansion and memory T cell induction J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-05-21 Lai, Peilong, Chen, Xiaomei, Wang, Yulian, Wang, Jinghua, Zhang, Yuchen, Geng, Suxia, Li, Peng, Du, Xin, Weng, Jianyu, Pei, Duanqing
Although chimeric antigen receptor (CAR)-modified adoptive T cell therapy is a promising immunotherapy for hematological malignancies, the efficacy improvement in relapsed/refractory acute lymphoblastic leukemia (ALL) with extramedullary infiltration and in multiple myeloma (MM) is still warranted. Since C3aR activation can promote the expansion of tumor-killing Th17 cells, we hypothesized that incorporating
-
Risk of SARS-CoV-2 Breakthrough Infection in Vaccinated Cancer Patients: A Retrospective Cohort Study J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-05-21 Rooney, Anthony, Bivona, Cory, Liu, Ben, Streeter, David, Gong, Han, Khan, Qamar
Although messenger RNA (mRNA) vaccines have established efficacy for prevention of severe SARS-CoV2 infection in the general population, their effectiveness in patients with malignancy, especially those on anti-neoplastic therapies, remains an area of open research. In order to better understand the risk of developing breakthrough SARS-CoV-2 infection and the outcomes associated with breakthrough infection
-
Safety of two-dose COVID-19 vaccination (BNT162b2 and CoronaVac) in adults with cancer: a territory-wide cohort study J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-05-19 Kang, Wei, Shami, Jessica J. P., Yan, Vincent K. C., Ye, Xuxiao, Blais, Joseph E., Li, Xue, Lee, Victor H. F., Chui, Celine S. L., Lai, Francisco T. T., Wan, Eric Y. F., Wong, Carlos K. H., Wong, Ian C. K., Chan, Esther W.
The World Health Organization has defined a list of adverse events of special interest (AESI) for safety surveillance of vaccines. AESI have not been adequately assessed following COVID-19 vaccination in patients with cancer contributing to vaccine hesitancy in this population. We aimed to evaluate the association between BNT162b2 and CoronaVac vaccines and the risk of AESI in adults with active cancer
-
Worked to the bone: antibody-based conditioning as the future of transplant biology J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-05-19 Griffin, James M., Healy, Fiona M., Dahal, Lekh N., Floisand, Yngvar, Woolley, John F.
Conditioning of the bone marrow prior to haematopoietic stem cell transplant is essential in eradicating the primary cause of disease, facilitating donor cell engraftment and avoiding transplant rejection via immunosuppression. Standard conditioning regimens, typically comprising chemotherapy and/or radiotherapy, have proven successful in bone marrow clearance but are also associated with severe toxicities
-
Post-transplant cyclophosphamide alters immune signatures and leads to impaired T cell reconstitution in allogeneic hematopoietic stem cell transplant J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-05-19 Zhao, Chenchen, Bartock, Matthew, Jia, Bei, Shah, Neal, Claxton, David F., Wirk, Baldeep, Rakszawski, Kevin L., Nickolich, Myles S., Naik, Seema G., Rybka, Witold B., Ehmann, W Christopher C., Hohl, Raymond J., Valentin, Jessica, Bernas-Peterson, Michelle, Gerber, Emily M., Zimmerman, Michele, Mierski, Joseph A., Mineishi, Shin, Zheng, Hong
Despite the increased usage of post-transplant cyclophosphamide (PTCy) in allogeneic hematopoietic stem cell transplantation (allo-HSCT), our knowledge of immune reconstitution post-allo-HSCT in the setting of PTCy is limited. Adequate immune reconstitution is the key to a successful transplant. In this study, we aim to investigate the effect of PTCy on the reconstitution of each immune component;
-
The potential role of N7-methylguanosine (m7G) in cancer J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-05-19 Luo, Yuejun, Yao, Yuxin, Wu, Peng, Zi, Xiaohui, Sun, Nan, He, Jie
N7-methylguanosine (m7G), one of the most prevalent RNA modifications, has recently attracted significant attention. The m7G modification actively participates in biological and pathological functions by affecting the metabolism of various RNA molecules, including messenger RNA, ribosomal RNA, microRNA, and transfer RNA. Increasing evidence indicates a critical role for m7G in human disease development
-
Homologous recombination deficiency (HRD) can predict the therapeutic outcomes of immuno-neoadjuvant therapy in NSCLC patients J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-05-18 Zhou, Zhen, Ding, Zhengping, Yuan, Jie, Shen, Shengping, Jian, Hong, Tan, Qiang, Yang, Yunhai, Chen, Zhiwei, Luo, Qingquan, Cheng, Xinghua, Yu, Yongfeng, Niu, Xiaomin, Qian, Liqiang, Chen, Xiaoke, Gu, Linping, Liu, Ruijun, Ma, Shenglin, Huang, Jia, Chen, Tianxiang, Li, Ziming, Ji, Wenxiang, Song, Liwei, Shen, Lan, Jiang, Long, Yu, Zicheng, Zhang, Chao, Tai, Zaixian, Wang, Changxi, Chen, Rongrong, Carbone
Neoadjuvant immunotherapy is emerging as novel effective intervention in lung cancer, but study to unearth effective surrogates indicating its therapeutic outcomes is limited. We investigated the genetic changes between non-small cell lung cancer (NSCLC) patients with varied response to neoadjuvant immunotherapy and discovered highly potential biomarkers with indicative capability in predicting outcomes
-
Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-05-18 Tie, Yan, Tang, Fan, Wei, Yu-quan, Wei, Xia-wei
Immunotherapies like the adoptive transfer of gene-engineered T cells and immune checkpoint inhibitors are novel therapeutic modalities for advanced cancers. However, some patients are refractory or resistant to these therapies, and the mechanisms underlying tumor immune resistance have not been fully elucidated. Immunosuppressive cells such as myeloid-derived suppressive cells, tumor-associated macrophages
-
Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-05-13 Eckardt, Jan-Niklas, Stölzel, Friedrich, Kunadt, Desiree, Röllig, Christoph, Stasik, Sebastian, Wagenführ, Lisa, Jöhrens, Korinna, Kuithan, Friederike, Krämer, Alwin, Scholl, Sebastian, Hochhaus, Andreas, Crysandt, Martina, Brümmendorf, Tim H., Naumann, Ralph, Steffen, Björn, Kunzmann, Volker, Einsele, Hermann, Schaich, Markus, Burchert, Andreas, Neubauer, Andreas, Schäfer-Eckart, Kerstin, Schliemann
Extramedullary manifestations (EM) are rare in acute myeloid leukemia (AML) and their impact on clinical outcomes is controversially discussed. We retrospectively analyzed a large multi-center cohort of 1583 newly diagnosed AML patients, of whom 225 (14.21%) had EM. AML patients with EM presented with significantly higher counts of white blood cells (p < 0.0001), peripheral blood blasts (p < 0.0001)
-
Single-cell sequencing: a promising approach for uncovering the mechanisms of tumor metastasis J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-05-12 Han, Yingying, Wang, Dan, Peng, Lushan, Huang, Tao, He, Xiaoyun, Wang, Junpu, Ou, Chunlin
Single-cell sequencing (SCS) is an emerging high-throughput technology that can be used to study the genomics, transcriptomics, and epigenetics at a single cell level. SCS is widely used in the diagnosis and treatment of various diseases, including cancer. Over the years, SCS has gradually become an effective clinical tool for the exploration of tumor metastasis mechanisms and the development of treatment
-
Tumor organoids: applications in cancer modeling and potentials in precision medicine J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-05-12 Xu, Hanxiao, Jiao, Dechao, Liu, Aiguo, Wu, Kongming
Cancer is a top-ranked life-threatening disease with intratumor heterogeneity. Tumor heterogeneity is associated with metastasis, relapse, and therapy resistance. These factors contribute to treatment failure and an unfavorable prognosis. Personalized tumor models faithfully capturing the tumor heterogeneity of individual patients are urgently needed for precision medicine. Advances in stem cell culture
-
Incidence, mortality, risk factors, and trends for Hodgkin lymphoma: a global data analysis J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-05-11 Huang, Junjie, Pang, Wing Sze, Lok, Veeleah, Zhang, Lin, Lucero-Prisno, Don Eliseo, Xu, Wanghong, Zheng, Zhi-Jie, Elcarte, Edmar, Withers, Mellissa, Wong, Martin C. S.
Hodgkin lymphoma is a lymphatic malignancy commonly found in cervical lymph nodes. This study evaluated the worldwide incidence, mortality, associated risk factors, and temporal trends of Hodgkin lymphoma by sex, age, and country. The age-standardised Hodgkin lymphoma incidence and mortality were retrieved from the GLOBOCAN, CI5 volumes I-XI, WHO mortality database, the NORDCAN and SEER Program. The
-
Pevonedistat in East Asian patients with acute myeloid leukemia or myelodysplastic syndromes: a phase 1/1b study to evaluate safety, pharmacokinetics and activity as a single agent and in combination with azacitidine J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-05-11 Handa, Hiroshi, Cheong, June-Won, Onishi, Yasushi, Iida, Hiroatsu, Kobayashi, Yukio, Kim, Hyeoung-Joon, Chiou, Tzeon-Jye, Izutsu, Koji, Tsukurov, Olga, Zhou, Xiaofei, Faessel, Helene, Yuan, Ying, Sedarati, Farhad, Faller, Douglas V., Kimura, Akiko, Wu, Shang-Ju
Pevonedistat, the first small-molecule inhibitor of NEDD8-activating enzyme, has demonstrated clinical activity in Western patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). We report findings from a phase 1/1b study in East Asian patients with AML or MDS, conducted to evaluate the safety/tolerability and characterize the pharmacokinetics of pevonedistat, alone or in combination
-
A novel role of lysophosphatidic acid (LPA) in human myeloma resistance to proteasome inhibitors J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-05-07 Su, Pan, Xiao, Liuling, Ye, Lingqun, Wang, Zhuo, Xiong, Wei, Wang, Qiang, Ma, Xingzhe, Xian, Miao, Yang, Maojie, Zu, Youli, Pingali, Sai Ravi, Qian, Jianfei, Yi, Qing
Lysophosphatidic acid (LPA) is a naturally occurring phospholipid that regulates cell proliferation, survival, and migration. However, its role on human multiple myeloma (MM) cells is largely unknown. In this study, we show that LPA, which is highly elevated in MM patients, plays an important role in protecting human MM cells against proteasome inhibitor (PI)-induced apoptosis. LPA bound to its receptor
-
SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-05-07 Piñana, José Luis, López-Corral, Lucia, Martino, Rodrigo, Vazquez, Lourdes, Pérez, Ariadna, Martin-Martin, Gabriel, Gago, Beatriz, Sanz-Linares, Gabriela, Sanchez-Salinas, Andrés, Villalon, Lucia, Conesa-Garcia, Venancio, Olave, María T., Corona, Magdalena, Marcos-Corrales, Sara, Tormo, Mar, Hernández-Rivas, José Ángel, Montoro, Juan, Rodriguez-Fernandez, Alicia, Risco-Gálvez, Irene, Rodríguez-Belenguer
The clinical efficacy of SARS-CoV-2 vaccines according to antibody response in immunosuppressed patients such as hematological patients has not yet been established. A prospective multicenter registry-based cohort study conducted from December 2020 to December 2021 by the Spanish transplant and cell therapy group was used to analyze the relationship of antibody response at 3–6 weeks after full vaccination
-
A novel tRNA-derived fragment AS-tDR-007333 promotes the malignancy of NSCLC via the HSPB1/MED29 and ELK4/MED29 axes J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-05-07 Yang, Wenhan, Gao, Kaiping, Qian, Youhui, Huang, Yongyi, Xiang, Qin, Chen, Cheng, Chen, Qianqian, Wang, Yiling, Fang, Fuyuan, He, Qihan, Chen, Siqi, Xiong, Juan, Chen, Yangchao, Xie, Ni, Zheng, Duo, Zhai, Rihong
Transfer RNA-derived fragments (tRFs) are a new class of small non-coding RNAs. Recent studies suggest that tRFs participate in some pathological processes. However, the biological functions and mechanisms of tRFs in non-small cell lung cancer (NSCLC) are largely unknown. Differentially expressed tRFs were identified by tRF and tiRNA sequencing using 9 pairs of pre- and post-operation plasma from patients
-
LncRNA-PACERR induces pro-tumour macrophages via interacting with miR-671-3p and m6A-reader IGF2BP2 in pancreatic ductal adenocarcinoma J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-05-07 Liu, Yihao, Shi, Minmin, He, Xingfeng, Cao, Yizhi, Liu, Pengyi, Li, Fanlu, Zou, Siyi, Wen, Chenlei, Zhan, Qian, Xu, Zhiwei, Wang, Jiancheng, Sun, Baofa, Shen, Baiyong
LncRNA-PACERR plays critical role in the polarization of tissue-associated macrophages (TAMs). In this study, we found the function and molecular mechanism of PACERR in TAMs to regulate pancreatic ductal adenocarcinoma (PDAC) progression. We used qPCR to analyse the expression of PACERR in TAMs and M1-tissue-resident macrophages (M1-NTRMs) which were isolated from 46 PDAC tissues. The function of PACERR
-
The dual role of autophagy in acute myeloid leukemia J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-05-07 Seo, Wonhyoung, Silwal, Prashanta, Song, Ik-Chan, Jo, Eun-Kyeong
Acute myeloid leukemia (AML) is a severe hematologic malignancy prevalent in older patients, and the identification of potential therapeutic targets for AML is problematic. Autophagy is a lysosome-dependent catabolic pathway involved in the tumorigenesis and/or treatment of various cancers. Mounting evidence has suggested that autophagy plays a critical role in the initiation and progression of AML
-
Correction: The long and short non-coding RNAs modulating EZH2 signaling in cancer J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-05-06 Mirzaei, Sepideh, Gholami, Mohammad Hossein, Hushmandi, Kiavash, Hashemi, Farid, Zabolian, Amirhossein, Canadas, Israel, Zarrabi, Ali, Nabavi, Noushin, Aref, Amir Reza, Crea, Francesco, Wang, Yuzhuo, Ashrafizadeh, Milad, Kumar, Alan Prem
The original article [1] contained an error in co-author, Farid Hashemi’s name which has since been corrected. Mirzaei S, Gholami MH, Hushmandi K, et al. The long and short non-coding RNAs modulating EZH2 signaling in cancer. J Hematol Oncol. 2022;15:18. https://doi.org/10.1186/s13045-022-01235-1. CAS Article PubMed PubMed Central Google Scholar Download references Affiliations Department of Biology
-
3D chromatin architecture and transcription regulation in cancer J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-05-04 Deng, Siwei, Feng, Yuliang, Pauklin, Siim
Chromatin has distinct three-dimensional (3D) architectures important in key biological processes, such as cell cycle, replication, differentiation, and transcription regulation. In turn, aberrant 3D structures play a vital role in developing abnormalities and diseases such as cancer. This review discusses key 3D chromatin structures (topologically associating domain, lamina-associated domain, and
-
Prostate cancer multiparametric magnetic resonance imaging visibility is a tumor-intrinsic phenomena J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-05-03 Khoo, Amanda, Liu, Lydia Y., Sadun, Taylor Y., Salmasi, Amirali, Pooli, Aydin, Felker, Ely, Houlahan, Kathleen E., Ignatchenko, Vladimir, Raman, Steven S., Sisk, Anthony E., Reiter, Robert E., Boutros, Paul C., Kislinger, Thomas
Multiparametric magnetic resonance imaging (mpMRI) is an emerging standard for diagnosing and prognosing prostate cancer, but ~ 20% of clinically significant tumors are invisible to mpMRI, as defined by the Prostate Imaging Reporting and Data System version 2 (PI-RADSv2) score of one or two. To understand the biological underpinnings of tumor visibility on mpMRI, we examined the proteomes of forty
-
Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-04-29 Lu, Yuting, Yuan, Xiangliang, Wang, Miao, He, Zhihao, Li, Hongzhong, Wang, Ji, Li, Qin
The gut microbiota have long been recognized to play a key role in human health and disease. Currently, several lines of evidence from preclinical to clinical research have gradually established that the gut microbiota can modulate antitumor immunity and affect the efficacy of cancer immunotherapies, especially immune checkpoint inhibitors (ICIs). Deciphering the underlying mechanisms reveals that
-
Universal immunotherapeutic strategy for hepatocellular carcinoma with exosome vaccines that engage adaptive and innate immune responses J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-04-29 Zuo, Bingfeng, Zhang, Yang, Zhao, Kangjie, Wu, Li, Qi, Han, Yang, Rong, Gao, Xianjun, Geng, Mengyuan, Wu, Yingjie, Jing, Renwei, Zhou, Qibing, Seow, Yiqi, Yin, HaiFang
Personalized immunotherapy utilizing cancer vaccines tailored to the tumors of individual patients holds promise for tumors with high genetic heterogeneity, potentially enabling eradication of the tumor in its entirety. Here, we demonstrate a general strategy for biological nanovaccines that trigger tailored tumor-specific immune responses for hepatocellular carcinoma (HCC). Dendritic cell (DC)-derived
-
Targeting nucleotide metabolism: a promising approach to enhance cancer immunotherapy J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-04-27 Wu, Huai-liang, Gong, Yue, Ji, Peng, Xie, Yi-fan, Jiang, Yi-Zhou, Liu, Guang-yu
Targeting nucleotide metabolism can not only inhibit tumor initiation and progression but also exert serious side effects. With in-depth studies of nucleotide metabolism, our understanding of nucleotide metabolism in tumors has revealed their non-proliferative effects on immune escape, indicating the potential effectiveness of nucleotide antimetabolites for enhancing immunotherapy. A growing body of
-
Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: a revisited perspective from molecular mechanisms to targeted therapies J. Hematol. Oncol. (IF 23.168) Pub Date : 2022-04-12 Liao, Minru, Qin, Rui, Huang, Wei, Zhu, Hong-Ping, Peng, Fu, Han, Bo, Liu, Bo
Triple-negative breast cancer (TNBC) is a subtype of human breast cancer with one of the worst prognoses, with no targeted therapeutic strategies currently available. Regulated cell death (RCD), also known as programmed cell death (PCD), has been widely reported to have numerous links to the progression and therapy of many types of human cancer. Of note, RCD can be divided into numerous different subroutines